- $12.31m
- $4.47m
- AU$4.90m
- 20
- 27
- 33
- 16
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.44 | ||
| Price to Tang. Book | 1.44 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 3.72 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -56.47% | ||
| Return on Equity | -42.92% | ||
| Operating Margin | -148.02% | ||
Financial Summary
| Year End 30th Jun | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | 2.52 | 0.15 | 0.77 | 1.8 | 4.9 | 5.5 | 15 | 15.48% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Immuron Limited is an Australia-based biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of infectious diseases. It operates through two segments: Research and development (R&D), and Hyperimmune products. The R&D segment is focused on R&D projects performed in Australia and the United States. Hyperimmune products segment is engaged in Travelan and Protectyn activities which occur predominantly in Australia, the United States and Canada. Its flagship products consist of Travelan and Protectyn. Travelan is an orally administered passive immunotherapy that prophylactically reduces the likelihood of contracting traveler’s diarrhea and is sold in pharmacies throughout Australia. Protectyn is sold online and in health practitioner clinics and is marketed as an immune supplement to help maintain a healthy digestive function and liver. Its clinical programs include Travelan (IMM-124E), IMM-529, and CampETEC.
Directors
- Roger Aston NEC
- Jerry Kanellos COO
- Dan Peres OTH
- Phillip Hains SEC
- Ravi Savarirayan DRC
- Stephen Anastasiou NED
- Daniel Pollock NED
- Last Annual
- June 30th, 2024
- Last Interim
- June 30th, 2024
- Incorporated
- January 13th, 1994
- Public Since
- April 30th, 1999
- No. of Employees
- 6
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 227,998,346
- Address
- L 3 62 Lygon St, MELBOURNE, 3053
- Web
- https://www.immuron.com.au
- Phone
- +61 398245254
- Auditors
- Grant Thornton Audit Pty Ltd
Upcoming Events for IMRN
Similar to IMRN
60 Degrees Pharmaceuticals
NASDAQ Capital Market
Aadi Bioscience
NASDAQ Capital Market
Agriforce Growing Systems
NASDAQ Capital Market
Altamira Therapeutics
NASDAQ Capital Market
Aptorum
NASDAQ Capital Market
FAQ
As of Today at 21:16 UTC, shares in Immuron are trading at $2.20. This share price information is delayed by 15 minutes.
Shares in Immuron last closed at $2.20 and the price had moved by +21.55% over the past 365 days. In terms of relative price strength the Immuron share price has underperformed the S&P500 Index by -9.54% over the past year.
The overall consensus recommendation for Immuron is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreImmuron does not currently pay a dividend.
Immuron does not currently pay a dividend.
Immuron does not currently pay a dividend.
To buy shares in Immuron you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $2.20, shares in Immuron had a market capitalisation of $12.31m.
Here are the trading details for Immuron:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: IMRN
Based on an overall assessment of its quality, value and momentum Immuron is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Immuron is $4.89. That is 122.14% above the last closing price of $2.20.
Analysts covering Immuron currently have a consensus Earnings Per Share (EPS) forecast of -AU$0.04 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Immuron. Over the past six months, its share price has underperformed the S&P500 Index by -27.73%.
As of the last closing price of $2.20, shares in Immuron were trading -6.55% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Immuron PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $2.20.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Immuron's management team is headed by:
- Roger Aston - NEC
- Jerry Kanellos - COO
- Dan Peres - OTH
- Phillip Hains - SEC
- Ravi Savarirayan - DRC
- Stephen Anastasiou - NED
- Daniel Pollock - NED